Maryland PDAB Requests Information On Four Drugs For Cost Review

Maryland’s Prescription Drug Affordability Board (PDAB) is requesting information by Aug. 26 for their cost review study process for Eli Lilly’s Trulicity, Novo Nordisk’s Ozempic, Boehringer Ingelheim’s Jardiance and AstraZeneca’s Farxiga. The four medications are part of the six the PDAB voted to move forward with for cost review studies. AbbVie’s Skyrizi and Sanofi’s Dupixent are the other two. According to the state’s PDAB statute, the cost review will determine whether the drug “has led or will lead to affordability...